// App-Quantinova.ai

5536 : A phase II evaluation of nivolumab, a fully human antibody against PD-1, in the treatment of persistent or recurrent cervical cancer.

Researchers

Presenter

  • Alessandro Santin

Principal Investigators

  • Wei Deng

  • Michael M. Frumovitz

  • Warner King Huh

  • Samir Khleif

  • Heather A. Lankes

  • Elena Ratner

  • Roisin O'Cearbhaill

  • Amir A. Jazaeri

  • Michael Birrer

Medical Centers

  • Yale University School of Medicine, New Haven, CT

  • Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Alabama at Birmingham, Birmingham, AL

  • Georgia Regents University Cancer Center, Augusta, GA

  • Gynecologic Oncology Group, Buffalo, NY

  • Yale University School of Medicine, New Haven, CT

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • University of Virgina, Charlottesville, VA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Programmed cell death protein 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02257528

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved